EGFR and non-small cell lung carcinoma: SCLC transformation is best characterized in the context of EGFR-mutant NSCLC, where it has been reported that 3–14% of patients undergo SCLC transformation as a mechanism of resistance to EGFR TKIs [6,8,9,13].